The product information provided in this site is intended only for emergency personnel and healthcare professionals in Canada only.
The products discussed herein may have different product labeling in different countries.
IMPORTANT SAFETY INFORMATION:
INDICATION AND CLINICAL USE: Cyanokit contains hydroxocobalamin, an antidote indicated for the treatment of known or suspected cyanide poisoning.
Cyanokit is to be administered together with appropriate decontamination and supportive measures.
CONTRAINDICATIONS: None. WARNINGS AND PRECAUTIONS: General: Emergency Patient Management - In addition to Cyanokit, treatment of cyanide poisoning must include immediate attention to airway patency, adequacy of oxygenation and hydration, cardiovascular support, and management of any seizure activity. Consideration should be given to decontamination measures based on the route of exposure. Cyanokit does not substitute for oxygen therapy and must not delay the set up of the above measures.
For important information on contraindications, warnings, precautions, adverse reactions, interactions and dosing, please consult the CYANOKIT Product Monograph.
The below video links are resources on the US website intended for US Healthcare practitioners. Prescribing information and directions for use may vary. Please refer to the Canadian product monograph for prescribing information. The links being provided are for your convenience only as we do not operate the www.cyanokit.com website. We cannot be responsible for content on third-party websites.
In Canada, For medical questions concerning CYANOKIT, to report an adverse event, please call 1-800-287-7686 ext. 7804.
®CYANOKIT is a registered trademark of SERB S.A., and is distributed in Canada by Methapharm Inc. © Copyright 2017 Methapharm Inc. - All Rights Reserved 2017. INDICATIONS AND CLINICAL USE: CYANOKIT contains hydroxocobalamin, an antidote indicated for the treatment of known or suspected cyanide poisoning. CYANOKIT is to be administered together with appropriate decontamination and supportive measures. For complete indication, contraindication, warnings and precautions see the CYANOKIT product monograph. References: 1. Eckstein M, Maniscalco PM. Focus on smoke inhalation–the most common cause of acute cyanide poisoning. Prehosp Disaster Med. 2006;21(2):s49-s55. 2. Guidotti T. Acute cyanide poisoning in prehospital care: new challenges, new tools for intervention. Prehosp Disaster Med. 2005;21(2):s40-s48. 3. CYANOKIT (single 5-g vial) [package insert]. Columbia, MD: Meridian Medical Technologies, Inc.; 2011 3. CYANOKIT (Hydroxocobalamin) Product Monograph. Date of Revision: July 5, 2016. Submission Control No: 195133.